By BENEDICT CAREY
Esketamine, the nasal-spray antidepressant recently approved by the F.D.A., is promising, but using it entails some practical challenges.
Published: March 7, 2019 at 07:00PM
from NYT Health https://ift.tt/2CltqTt
via IFTTT
from WordPress https://ift.tt/2NOVnHw
via IFTTT
No comments:
Post a Comment